Skip to main content

Advertisement

SpringerLink
Log in

Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Zoledronic acid (ZA) delays the onset or reduces the incidence of skeletal complications in breast cancer patients with bone metastases. However, there are few data on the long-term renal safety of ZA. We retrospectively evaluated 43 breast cancer patients with bone metastases who received ZA more than 24 months. The following parameters measured prior to first ZA use and after the last dose of ZA administration were compared: serum creatinine (SCr), blood urea nitrogen (BUN), alkaline phosphatase (ALP), calcium (Ca), and phosphorous (P). Forty-three breast cancer patients with documented bone metastases were evaluated. Median age at the start of treatment was 53 years (range 37–77). Median overall duration of ZA administration was 36 months (25–62). There were no statistically significant differences in the pre- and post-treatment levels of SCr, BUN, Ca and P. However, ALP levels after long-term ZA administration were decreased significantly (P < 0.05). More than 24 months of ZA administration did not adversely affect the renal function. ZA can be used safely in breast cancer patients with bone metastases beyond 2 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Manders K, van de Poll-Franse LV, Creemers GJ. Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer. 2006;6:179.

    Article  PubMed  Google Scholar 

  2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165–76.

    Article  PubMed  CAS  Google Scholar 

  3. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005(3):CD003474.

  4. Lipton A. Management of bone metastases in breast cancer. Curr Treat Options Oncol 2005;6:161–71.

    Article  PubMed  Google Scholar 

  5. Bounameaux HM, et al. Renal failure associated with intravenous diphosphonates. Lancet 1983;1:471.

    Article  PubMed  CAS  Google Scholar 

  6. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999;21:389–406.

    Article  PubMed  CAS  Google Scholar 

  7. Markowitz GS, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281–9.

    Article  PubMed  CAS  Google Scholar 

  8. Ali SM, Esteva FJ, Hortobagyi G. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001;19:3434–7.

    PubMed  CAS  Google Scholar 

  9. Guarneri V, Donati S, Nicolini M, Giovannelli S, D’Amico R, Conte PF. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist. 2005;10:842–8.

    Article  PubMed  CAS  Google Scholar 

  10. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897–907.

    Article  PubMed  CAS  Google Scholar 

  11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.

    Article  PubMed  CAS  Google Scholar 

  12. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676–9 (discussion 1676–9.).

    Article  PubMed  CAS  Google Scholar 

  13. Markowitz GS, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12:1164–72.

    PubMed  CAS  Google Scholar 

  14. Gokden N, et al. Potential effect of zoledronate therapy in heavy proteinuria. Clin Nephrol 2007;67:263–5.

    PubMed  CAS  Google Scholar 

  15. Balla J. The issue of renal safety of zoledronic acid from a nephrologist’s point of view. Oncologist 2005;10:306–8.

    Article  PubMed  Google Scholar 

  16. Altundag O, et al. Calcium and vitamin D supplementation during bisphosphonate administration may increase osteoclastic activity in patients with bone metastasis. Med Hypotheses. 2004;63:1010–3.

    Article  PubMed  CAS  Google Scholar 

  17. Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suarez MA, Aguiar Morales J. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 2007;18:556–60.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Institute of Oncology, Sihhiye, 06100, Ankara, Turkey

    Murat Dincer, Kadri Altundag, Hakan Harputluoglu, Sercan Aksoy & Ibrahim Gullu

  2. Department of Radiation Oncology, Hacettepe University Institute of Oncology, Sihhiye, 06100, Ankara, Turkey

    Mustafa Cengiz

Authors
  1. Murat Dincer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kadri Altundag
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hakan Harputluoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sercan Aksoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mustafa Cengiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ibrahim Gullu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kadri Altundag.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dincer, M., Altundag, K., Harputluoglu, H. et al. Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases. Med Oncol 25, 356–359 (2008). https://doi.org/10.1007/s12032-008-9045-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-008-9045-3

Keywords

Search

Navigation